Welcome to our dedicated page for Merck & news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & stock.
Merck & Co., Inc. reports news across a global pharmaceutical business known as MSD outside the United States and Canada. Company updates center on human health products for areas such as oncology, cardiometabolic disease and infections; vaccines including Gardasil; and Merck Animal Health medicines, devices and customer-support systems.
Recurring developments include FDA approvals, clinical and regulatory disclosures, research publications, pipeline additions, business development transactions, material agreements, capital-structure updates, governance matters, and operating and financial results. Recent themes include the approved HIV-1 regimen IDVYNSO, investigational programs such as enlicitide decanoate and TERN-701, technology partnerships for research, manufacturing and commercial functions, and animal health digital engagement initiatives.
Merck (NYSE: MRK) reported late-breaking Phase 3 KEYNOTE-B15 results showing perioperative KEYTRUDA plus Padcev reduced risk of event-free survival events by 47% and risk of death by 35% versus neoadjuvant chemotherapy in cisplatin-eligible muscle-invasive bladder cancer after 33.6 months' median follow-up.
Median EFS and OS were not reached for the combination; pathologic complete response rose to 55.8% versus 32.5%. Grade ≥3 adverse events were higher with the combination (75.7% vs 67.2%).
Merck Animal Health (NYSE:MRK) announced FDA approval of NUMELVI (atinvicitinib) tablets for control of pruritus associated with allergic dermatitis in dogs six months and older. The product is expected to be available at veterinary clinics nationwide in spring 2026.
NUMELVI is described as a second-generation JAK inhibitor with high JAK1 selectivity, once-daily dosing, dosing for dogs from 4.4 pounds, standard storage, and an extended shelf life among JAK inhibitor tablets.
Merck (NYSE: MRK) presented late-breaking Phase 3 data for investigational doravirine/islatravir (DOR/ISL) as a once-daily, two-drug, non-INSTI regimen for adults with HIV-1.
In treatment-naïve adults DOR/ISL met non-inferiority at Week 48 (91.8% vs 90.6%; difference 1.2%, 95% CI -3.7, 6.2) and maintained viral suppression at Week 96 in switch studies. The U.S. FDA PDUFA target action date for the NDA is April 28, 2026.
Merck (NYSE: MRK) will participate in the TD Cowen 46th Annual Health Care Conference on Mar. 3, 2026. Caroline Litchfield, executive vice president and CFO, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, will take part in a fireside chat at 1:50 p.m. EST.
Investors, analysts, media and the public may listen via a live audio webcast at the company-provided weblink.
Merck (NYSE: MRK) is reorganizing its Human Health operating structure into two business units: Oncology and Specialty, Pharma & Infectious Diseases. Jannie Oosthuizen is appointed EVP and president, Oncology and MSD International; Brian Foard joins as EVP and president, Specialty, Pharma & Infectious Diseases effective March 2, 2026.
The company said it is conducting approximately 80 Phase 3 studies and expects >20 new growth drivers over the next several years, aiming to support multiple forthcoming launches and sustained commercial execution.
Merck (NYSE: MRK) reported positive Phase 3 SMART trial second RSV season data for ENFLONSIA (clesrovimab) in infants and children under 2 years at increased risk for severe RSV disease (presented Feb 19, 2026).
Safety in season 2 was generally consistent with season 1, serum concentrations matched pivotal CLEVER trial levels, and results support extrapolation of efficacy and regulatory submissions for an expanded indication through a second RSV season.
Merck (NYSE: MRK) and Mayo Clinic announced a research and development collaboration on February 18, 2026 to apply AI, advanced analytics and multimodal clinical data to support drug discovery and development.
The agreement gives Merck access to Mayo Clinic Platform data—de-identified clinical, genomic, imaging and molecular datasets—plus AI tools, registries and biorepositories to validate AI models and inform target identification in IBD, atopic dermatitis and multiple sclerosis.
Merck (NYSE: MRK) will present multiple genitourinary cancer data sets at the 2026 ASCO GU Cancers Symposium (Feb 26–28, 2026), including Phase 3 KEYNOTE-B15 showing significant improvements in event-free survival, overall survival and pathologic complete response for KEYTRUDA plus Padcev in muscle-invasive bladder cancer.
Additional featured results include LITESPARK-022 (adjuvant KEYTRUDA plus WELIREG) showing disease-free survival benefit and LITESPARK-011 (WELIREG plus LENVIMA) showing progression-free survival benefit in renal cell carcinoma.
Merck (NYSE: MRK) announced FDA approval of KEYTRUDA and KEYTRUDA QLEX plus paclitaxel, with or without bevacizumab, for adults with PD-L1+ (CPS ≥1) platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma after one or two prior systemic regimens.
Approvals are based on Phase 3 KEYNOTE-B96: PFS HR 0.72 (28% risk reduction; p=0.0014), median PFS 8.3 vs 7.2 months; OS HR 0.76 (24% risk reduction; p=0.0053), median OS 18.2 vs 14.0 months. Safety signals include 54% serious adverse reactions and 3.9% fatal reactions.
Merck (NYSE: MRK) reported fourth-quarter 2025 worldwide sales of $16.4 billion (+5% / +4% ex-FX) and full-year sales of $65.0 billion (+1% / +2% ex-FX). Fourth-quarter GAAP EPS was $1.19 and non-GAAP EPS was $2.04; full-year GAAP EPS was $7.28 and non-GAAP EPS was $8.98. Key drivers included KEYTRUDA sales of $31.7 billion (+7%), strong Animal Health performance ($6.4 billion, +8%), and rising contributions from WINREVAIR and CAPVAXIVE. The company completed acquisitions of Verona Pharma and Cidara, reported positive Phase 3 readouts, and set 2026 sales outlook of $65.5–$67.0 billion with non-GAAP EPS guidance of $5.00–$5.15 (includes a one-time ~$3.65 per-share charge).